Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Wild Ride For Immunology? New Mechanisms, Big Indications Up For US FDA Approval In 2022

Feb 09 2022

• By Bridget Silverman

Wild Metallic Ride — • Source: Alamy

Related Content

Patient-Focused Meeting On Vitiligo Could Galvanize R&D As The First Drug Candidates In A Long Time Advance

Apr 20 2021

US FDA Restricts JAK Inhibitors To Second-Line In Rheumatoid Arthritis Amid CV, Cancer, Mortality Risks

Sep 02 2021

Lilly’s Eczema Contender Promising, But Needs Head-To-Head Data To Dent Dupixent Dominance

Aug 16 2021

Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval

Sep 22 2021

Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis

Oct 07 2021

Boehringer Targets High Unmet Need With Spesolimab Filing

Nov 05 2021

Dermatology To Become A Key Franchise For Incyte

Dec 15 2021

Lilly Says Safety Not A Factor In Dropping Lupus Development With Olumiant

Jan 28 2022

Big Year For UCB As Bimzelx Awaits US Green Light

Jan 20 2022

Pfizer And AbbVie JAKs Finally Join Dupixent In US Atopic Dermatitis Space

Jan 17 2022

AbbVie Says Rinvoq Holding Up, Humira Erosion Will Continue Into 2024

Feb 02 2022

Related Companies

Pfizer Inc.

AbbVie Inc.

Regeneron Pharmaceuticals, Inc.

Sanofi

LEO Pharma A/S

Eli Lilly and Company

Incyte Corporation

UCB S.A.

Dermavant Sciences Inc.

Arcutis Biotherapeutics, Inc.

Bristol Myers Squibb Company

Concert Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Additional Topics

United States Drug Approval Standards Drug Review Drug Safety Regulation Immune Disorders Pink Sheet Perspectives BioPharmaceutical

More from Pink Sheet Perspectives

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window